Open AccessLong-term outcome of (neo)adjuvant zoledronic acid therapy in locally advanced breast cancer
Author(s) -
Andrew P. Jallouk,
Sriram S. Paravastu,
Katherine N. Weilbaecher,
Rebecca Aft
Publication year - 2021
Publication title -
breast cancer research and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.908
H-Index - 154
eISSN - 1573-7217
pISSN - 0167-6806
DOI - 10.1007/s10549-021-06100-2
Subject(s) - medicine , zoledronic acid , breast cancer , chemotherapy , oncology , population , bisphosphonate , cancer , osteoporosis , environmental health
The role of zoledronic acid (ZOL), a bone-targeted bisphosphonate, in the treatment of patients with breast cancer remains an active area of study. Here, we report the long-term outcomes of a randomized placebo-controlled phase II clinical trial in which ZOL treatment was added to neoadjuvant chemotherapy in women with locally advanced breast cancer.